Formulation Guide
Extended-Release
Controlled-release matrix, coating, or osmotic system
This tool shows mechanism, verdict, and alternative data only — not patient-specific advice. A “can crush” result is a general guide, not a guarantee for your exact product: the same ingredient can differ by brand, manufacturer, and formulation. Data comes from U.S. drug labels and covers a limited set of medicines — if a drug isn’t listed, that is not a green light to crush it. Always confirm with your pharmacist or physician before altering how a medication is administered.
How it works
Extended-release formulations slow drug delivery over 8–24 hours using one of several mechanisms: (1) Matrix systems embed the active ingredient in a hydrophilic or hydrophobic polymer network (HPMC, ethyl cellulose, polyox) that swells and erodes to release drug gradually. (2) Membrane-coated reservoir systems surround a drug core with a rate-controlling polymer film. (3) Osmotic-pump systems (OROS/GITS) use a semipermeable membrane and an osmotic agent to push drug solution out through a laser-drilled orifice at a near zero-order rate independent of gastrointestinal pH or motility. All three approaches achieve near-constant plasma concentrations and reduce peak-to-trough fluctuation compared with immediate-release dosing. Product labels rarely specify which mechanism is used — ER, XL, XR, CD, SR, OROS, and GITS suffixes may each represent any of them.
Why crushing or splitting is risky
Crushing any extended-release tablet destroys the release mechanism entirely, regardless of which system the manufacturer used. The result is immediate availability of the entire dose — dose dumping — causing a rapid, uncontrolled spike in plasma concentration. For narrow-therapeutic-index drugs such as metoprolol succinate, diltiazem, nifedipine OROS, oxycodone ER, and methylphenidate OROS, this can result in dangerously low blood pressure, respiratory depression, cardiac events, or life-threatening toxicity.